These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31782368)

  • 41. Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity.
    Bulut H; Hattori SI; Aoki-Ogata H; Hayashi H; Das D; Aoki M; Davis DA; Rao KV; Nyalapatla PR; Ghosh AK; Mitsuya H
    Sci Rep; 2020 Jun; 10(1):10664. PubMed ID: 32606378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
    Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
    Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Localization of gene products using a chromosomally tagged GFP-fusion library in the fission yeast Schizosaccharomyces pombe.
    Hayashi A; Ding DQ; Tsutsumi C; Chikashige Y; Masuda H; Haraguchi T; Hiraoka Y
    Genes Cells; 2009 Feb; 14(2):217-25. PubMed ID: 19170768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.
    Louis JM; Tözsér J; Roche J; Matúz K; Aniana A; Sayer JM
    Biochemistry; 2013 Oct; 52(43):7678-88. PubMed ID: 24079831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
    Kar P; Lipowsky R; Knecht V
    J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A yeast-based high-throughput screen for modulators of phosphodiesterase activity.
    de Medeiros AS; Hoffman CS
    Methods Mol Biol; 2015; 1294():181-90. PubMed ID: 25783886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative assessment of in vivo HIV protease activity using genetically engineered QD-based FRET probes.
    Cella LN; Biswas P; Yates MV; Mulchandani A; Chen W
    Biotechnol Bioeng; 2014 Jun; 111(6):1082-7. PubMed ID: 24473897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.
    Dautin N; Karimova G; Ullmann A; Ladant D
    J Bacteriol; 2000 Dec; 182(24):7060-6. PubMed ID: 11092869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
    J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
    Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
    Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Visualization of human immunodeficiency virus protease inhibition using a novel Förster resonance energy transfer molecular probe.
    Jin S; Ellis E; Veetil JV; Yao H; Ye K
    Biotechnol Prog; 2011 Jul; 27(4):1107-14. PubMed ID: 21584951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
    Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
    J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-1 protease-substrate coevolution in nelfinavir resistance.
    Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
    J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
    Hoffmann D; Buchberger B; Nemetz C
    J Clin Virol; 2005 Apr; 32(4):294-9. PubMed ID: 15780808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.
    Doherty KM; Nakka P; King BM; Rhee SY; Holmes SP; Shafer RW; Radhakrishnan ML
    BMC Bioinformatics; 2011 Dec; 12():477. PubMed ID: 22172090
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
    Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
    J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.